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Background. During the last years, neutrophils have emerged as important players in atherogenesis. They are highly activated
in peripheral blood of patients with unstable angina. Moreover, a primed state of circulating neutrophils has been proposed in
patients with stable angina. Our aim was to investigate the neutrophil activation status in patients with stable coronary artery
disease (CAD) at conventional drug treatment. Methodology and Principal Findings. Thirty patients with stable CAD and 30
healthy controls were included using a paired design. The neutrophil expression of CD18 and high-affinity state of CD11b was
analysed by flow cytometry before and after stimulation with chemoattractants. Also, the production of reactive oxygen
species (ROS) was determined by chemiluminescence. During basal conditions, the neutrophil expression of CD18 or high-
affinity state of CD11b did not differ between patients and controls. Chemoattractants (Interleukin-8 and Leukotriene B4) did
not increase either the expression or the amount of high-affinity CD11b/CD18-integrins in CAD patients compared to controls,
and had no effect on the production of ROS. On the other hand, the ROS production in response to C3bi-opsonised yeast
particles and the neutrophils’ inherent capacity to produce ROS were both significantly decreased in patients. Conclusion/
Significance. We could not find any evidence that neutrophils in patients with stable CAD were primed, i.e. more prone to
activation, compared to cells from healthy controls. According to our data, the circulating neutrophils in CAD patients rather
showed an impaired activation status. It remains to be elucidated whether the neutrophil dysfunction in CAD is mainly
a marker of chronic disease, an atherogenic factor or a consequence of the drug treatment.
Citation: Sa ¨rndahl E, Bergstro ¨m I, Brodin VP, Nijm J, Setterud HL, et al (2007) Neutrophil Activation Status in Stable Coronary Artery Disease. PLoS
ONE 2(10): e1056. doi:10.1371/journal.pone.0001056
INTRODUCTION
During the last decade, new knowledge on neutrophils as active
participants in the inflammatory process of atherosclerosis has
emerged. Systemic inflammation, involving activated neutrophils,
is clearly associated with unstable conditions of CAD [1–4].
Moreover, increased numbers of circulating neutrophils is a well
known risk indicator of future cardiovascular outcomes, regardless
of disease status (reviewed in:[5]). However, the neutrophil
activation status in patients with stable CAD has received less
consideration and data have so far been inconsistent. Whereas
some studies give no evidence for an on-going in vivo neutrophil
activation [6,7], others have shown that neutrophils in patients
with established CAD or in individuals at high risk for vascular
events possess a ‘‘primed’’ character, i.e. an increased functional
potential ex vivo compared to neutrophils from healthy individuals
[6,8–10]. In addition, the accumulation of neutrophil-platelet
complexes, a possible indicator of neutrophil activation, has been
demonstrated in peripheral blood of CAD patients with long-term
stable symptoms [7,11].
The early phase of atherosclerosis involves the recruitment of
inflammatory cells from the circulation to the arterial wall [12,13].
This process is predominantly mediated by cellular adhesion
molecules, expressed on the vascular endothelium and on
circulating leukocytes. Two of the most important adhesion
molecules, expressed exclusively by leukocytes, are CD11a/CD18
(LFA-1) and CD11b/CD18 (Mac-1 or complement receptor 3),
which belong to the b2-integrin family [14]. Neutrophils in
patients with acute coronary symptoms display increased number
of b2-integrins compared to patients with stable CAD [7,11],
while no up-regulation of CD11b/CD18 has been found on
neutrophils from patients with stable CAD compared to healthy
controls [7,10,11]. However, the absolute number of integrins on
the cell surface does not necessarily reflect their functional role. To
obtain binding of neutrophils to the vascular endothelium, b2-
integrins must be turned into an active state; a process
accomplished via receptors for chemokines and chemotactic
factors by a so called inside-out signalling [15]. Integrins have
been suggested to increase their adhesive properties through
inside-out signalling by two distinct mechanisms [16]; the first
being a change in affinity for the ligand, and the second involving
changes in lateral surface motility and clustering of integrins. An
increase in b2-integrin affinity is achieved by conformational
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PLoS ONE | www.plosone.org 1 October 2007 | Issue 10 | e1056changes of the integrin, thereby exposing an epitope that enables
ligand binding, the so called I-domain [17].
In the present study, we hypothesized that neutrophils in
patients with stable CAD were in a primed or pre-activated state
compared to neutrophils in healthy individuals. The neutrophil
activation status, involving the expression, affinity state and
signalling capacity of b2-integrins during basal and stimulatory
conditions as well as the innate ROS production, was investigated
in a paired patient-control design.
RESULTS
Clinical and laboratory characteristics of subjects
Clinical and laboratory characteristics of patients and controls are
given in Table 1. The use of medication differed significantly
between the two groups. A small number of controls received
treatment with low-dose aspirin, beta-blockers, angiotensin-con-
verting enzyme inhibitors or statins due to the presence of risk
factors, such as hypertension and hyperlipidemia. There were no
differences in the amount of C-reactive protein (CRP) or leukocyte
blood count between patients and controls.
Baseline expression and high-affinity state of b2-
integrins on neutrophils
Using flow cytometry, the mean fluorescence intensity (MFI) values
revealed that patients with stable CAD and control subjects
expressed the same amount of b2-integrins on their neutrophils
(349680 and 3376104, respectively; mean MFI6SD; Fig. 1A,C).
Also, no differences in the amount of b2-integrins exposing the high-
affinity epitope could be detected when comparing neutrophils from
patients and controls (1968a n d2 4 612, respectively; Fig. 1B,D).
b2-integrin up-regulation on neutrophils upon IL-8
or LTB4 stimulation
The pro-inflammatory chemoattractants IL-8 and LTB4 were used
to study up-regulation of b2-integrins on neutrophils. In both
patients and healthy individuals, stimulation with IL-8 induced an
up-regulation of b2-integrins (148%630 and 152%637, respective-
ly; Fig. 2A,C), and an even stronger up-regulation was induced by
LTB4 (172%637 and 180%638, respectively; Fig. 2B,D) compared
to unstimulated cells. No significant difference was detected between
patients and controls in regard to the total expression of b2-integrins
(Fig. 2C and D) or in the increased percentage of up-regulated b2-
integrins upon chemoattractant stimulation (data not shown).
The expression of high-affinity state b2-integrins on
neutrophils upon IL-8 or LTB4 stimulation
The inside-out regulation of the high-affinity b2-integrins was
evaluated in neutrophils stimulated with IL-8 or LTB4. Stimula-
tion with IL-8 (Fig. 3A–B) and LTB4 (Fig. 3C–D) induced
a prominent increase in the amount of CD11b exposing the high-
affinity epitope compared to unstimulated neutrophils in both
patients and controls (230%681 and 225%676; 308%6102 and
316%695, respectively). No significant difference in the total
number of high-affinity b2-integrins (Fig. 3B and D) or in the
increased percentage of high-affinity b2-integrins (data not shown)
was detected between neutrophils from patients and controls upon
chemoattractant stimulation
b2-integrin signalling capacity in neutrophils
The signalling capacity of b2-integrins on neutrophils was
determined by measuring ROS production in response to C3bi-
opsonized yeast particles. We found that neutrophils from the
patients produced significantly lower levels of ROS compared to
their individually matched controls (with a mean reduction of
30%617; Fig. 3E–F). In support of previous studies on neutrophils
from healthy blood donors [18], the production of ROS elicited by
C3bi-opsonized yeast particles in neutrophils isolated from
patients was mainly intracellular (data not shown).
ROS production in neutrophils upon IL-8 or LTB4
stimulation
To investigate if neutrophils from patients with stable CAD
displayed a more primed character, the total ROS production (i.e.
intracellularly produced plus extracellularly released) was mea-
sured in response to IL-8 and LTB4. Both IL-8 and LTB4 elicited
mainly extracellular ROS production (data not shown). The ROS
responses were of the same magnitude in neutrophils from patients
as in neutrophils from controls (Fig. 4A–D). However, PMA (i.e.
a non-receptor mediated response) elicited significantly lower
production of ROS in neutrophils from patients compared to
neutrophils from individually matched controls, with a mean
reduction of 21%612 (Fig. 4E–F).
Table 1. Clinical and laboratory characteristics of patients and
controls.
......................................................................
Patients Controls p values
Total no. 30 30 ns
Female/Male (no.) 5/25 5/25 ns
Age (years) 63 (59–67)
1) 63 (60–68) ns
Smokers n (%) 4 (13) 4 (13) ns
Blood pressure (mm Hg)
Systolic 135 (120–146) 141 (130–152) ns
Diastolic 83 (78–91) 84 (78–92) ns
Body mass index (kg/m
2) 27 (24–29) 25 (24–29) ns
Medication n (%)
Beta blockers 28 (93) 3 (10) ,0.001
ACE-I/ARB
2) 16 (52) 2 (7) ,0.001
Statin 30 (100) 3 (10) ,0.001
Low-dose Aspirin 30 (100) 1 (3) ,0.001
Laboratory variables
3)
CRP
4) (mg/mL) 0.9 (0.3–1.8) 1.2 (0.4–2.2) ns
Blood glucose (mmol/l) 5.1 (4.4–5.9) 5.8 (5.2–6.5) ,0.01
Lipids (mmol/l)
Total cholesterol 4.5 (4.1–5.0) 5.2 (5.0–6.0) ,0.01
Low-density lipoprotein (LDL)
cholesterol
2.2 (1.9–2.8) 2.9 (2.5–3.4) ,0.05
High-density lipoprotein (HDL)
cholesterol
1.4 (1.2–1.6) 1.5 (1.3–2.1) ns
Triglycerides 1.5 (1.0–1.9) 1.2 (0.9–1.8) ns
Blood count (cells/mL)
Leukocytes 6.1 (5.3–6.8) 5.6 (4.8–6.7) ns
Neutrophils 3.0 (2.6–3.5) 2.7 (2.3–3.9) ns
1)Data are given as median (inter-quartile range).
2)ACE-I, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor
blockade
3)Measured at the accredited clinical chemistry laboratory at Linko ¨ping
University Hospital, Sweden.
4)CRP, C-reactive protein
doi:10.1371/journal.pone.0001056.t001
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Leukocytes in Coronary Disease
PLoS ONE | www.plosone.org 2 October 2007 | Issue 10 | e1056Figure 1. Baseline expression of CD18 and high-affinity state CD11b on neutrophils in patients with stable CAD. Whole blood from patients (P)
and individually matched control persons (C) were incubated at 37uC with (A,C) the MHM23-antibody or with (B,D) the CBRM1/5-antibody for 5 and
10 min, respectively, whereafter the samples were incubated on ice. Contaminating erythrocytes were removed by lysis, and antibody bound to
CD18 or to CD11b-integrins displaying the high-affinity epitope was detected by FACS analysis. The cells were gated to identify the neutrophil
population, and 10 000 cells were analyzed in each sample. Data are shown as one representative histogram plot (A,B) or as median of the mean
fluorescence intensity (MFI) values (C,D) from 30 (A,C) and 25 (B,D) experiments per cohort done in triplicate. Mean value is indicated as a black
hyphen. Wilcoxon signed-ranks test was used to determine significance between each patient and its individually matched control.
doi:10.1371/journal.pone.0001056.g001
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PLoS ONE | www.plosone.org 3 October 2007 | Issue 10 | e1056Figure 2. IL-8 and LTB4 induced expression of CD18 on neutrophils from patients with stable CAD. Whole blood from patients (P) and individually
matched control persons (C) were stimulated for 10 min at 37uC with (A,C) IL-8 (10 ng/mL) or (B,D) LTB4 (100 nM), and the samples were co-
incubated with the MHM23-antibody during the last 5 min of stimulation. The stimulation was stopped by incubation the samples on ice, and
contaminating erythrocytes were removed by lysis. Antibody bound to CD18 was detected by FACS analysis. The cells were gated to identify the
neutrophil population, and 10 000 cells were counted in each sample. Data are shown as one representative histogram plot (A,B) or as median of the
mean fluorescence intensity (MFI) values (C,D) from 22 (A,C) and 30 (B,D) experiments per cohort done in triplicate. Mean value is indicated as a black
hyphen. Wilcoxon signed-ranks test was used to determine significance between each patient and its individually matched control.
doi:10.1371/journal.pone.0001056.g002
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PLoS ONE | www.plosone.org 4 October 2007 | Issue 10 | e1056DISCUSSION
The present study investigated the activation status of neutrophils
in patients with stable CAD by determining the cells adhesive
property and their ability to produce ROS. We found that the
baseline expression of b2-integrins did not differ between
neutrophils in patients and healthy controls; neither did the
amount of b2-integrins exposing the high-affinity epitope. The
results are in line with previous reports showing similar levels of
b2-integrins on neutrophils in patients with stable CAD as in
healthy controls [6,7,10,11]. However, the number of integrins on
the neutrophil surface does not reflect the functional state of the
integrin. In order to enable cellular adhesion, a conformational
change of the b2-integrin is needed to increase its affinity [19].
Our results, demonstrating similar levels of high-affinity CD11b-
integrin in patients with stable CAD as in healthy controls, provide
new knowledge and extend thereby data from previous reports [6,7];
also contradicting an in vivo neutrophil activation in stable CAD.
IL-8 and LTB4 are both potent leukocyte chemoattractants,
known to promote several inflammatory disorders, including
atherosclerosis. Serum levels of IL-8 are elevated in patients with
stable CAD [20], and in healthy individuals elevated levels of IL-8
are associated with an increased risk of future CAD [21]. As
expected, the expression and affinity of b2-integrins, as well as the
ROS production were increased in neutrophils upon stimulation
with IL-8 or LTB4. However, these stimuli-induced responses of
neutrophils in patients were comparable to the ones detected in
healthy individuals. Data from previous studies have suggested
Figure 3. IL-8 and LTB4-induced expression of high-affinity state CD11b on neutrophils from patients with stable CAD. (A–D) Whole blood from
patients (P) and individually matched control persons (C) were incubated for 1 min with CBRM1/5 at 37uC, before stimulated for 10 min with (A–B) IL-
8 (10 ng/mL) or (C–D) LTB4 (100 nM) at 37uC. The stimulation was stopped by incubating the samples on ice, and contaminating erythrocytes were
removed by lysis. Antibody recognizing integrins displaying the high-affinity epitope was detected by FACS analysis. The cells were gated to identify
the neutrophil population, and 10 000 cells were counted in each sample. Data are shown as one representative histogram plot (A,C) or as median of
the mean fluorescence intensity (MFI) values (B,D) from 20 (A–B) and 25 (C–D) experiments per cohort done in triplicate. (E–F) Isolated neutrophils
from patients and control persons were stimulated with C3bi-opsonized yeast particles (5610
6/mL), and the production of ROS was measured
continuously for 60 min at 37uC. Data are expressed as counts per min (cpm) and shown as one representative histogram plot (E) or as total ROS
production peak value from 10 experiments per cohort (F). Mean value is indicated as a black hyphen. Wilcoxon signed-ranks test was used to
determine significance between each patient and its individually matched control (** represents significant difference; p,0.01).
doi:10.1371/journal.pone.0001056.g003
Leukocytes in Coronary Disease
PLoS ONE | www.plosone.org 5 October 2007 | Issue 10 | e1056that neutrophils in patients with stable CAD or in individuals at
high risk for vascular events possess a primed character compared
to neutrophils from healthy individuals, i.e. the cells are
‘‘hyperactive’’ ex vivo as assessed by increased chemotactic activity
and increased production of ROS, LTB4 and IL-8 [6,8,9].
However, our data could not support the hypothesis that
neutrophils in patients with stable CAD are more prone to
activation.
In a recently published study, a different approach was used to
study neutrophil activation. In a small group of CAD patients,
a skin blister model was applied in order to describe trans-
migration of neutrophils at different stages of interstitial in-
flammation [10]. In vivo transmigrated neutrophils in patients
showed an increased capacity to release gelatine-associated
lipocalin and matrix metalloproteinase-9 in a milieu of in-
termediate, but not intense, inflammation. The authors thereby
proposed that the dysfunctional neutrophil response in CAD
patients was a consequence of a primed state of circulating
neutrophils. It is possible that the stimulation with IL-8 and LTB4,
used in our study, represented a too intense inflammatory state in
which a primed character of the neutrophils was abolished by e.g.
receptor desensitization [22,23]. Arguing against this is that IL-8
and LTB4 are intermediate chemoattractants, known to induce
more moderate cellular responses [24]. In addition, it could be
argued that the stimulation with IL-8 and LTB4 is a more
clinically relevant model with regard to atherosclerosis than the
skin blister model [10].
An aberrant neutrophil activation status in atherosclerosis, not
only involving priming but also refractivity to further stimulation,
has been discussed. Paulsson and co-workers [10] found that in vivo
transmigrated neutrophils in CAD patients had a reduced capacity
to up-regulate CD11b and to produce H2O2 compared to
neutrophils in healthy controls. In the present study, we show
that neutrophils in patients with stable CAD possessed a functional
inside-out regulation in relation to b2-integrin expression and
affinity. However, upon stimulation with C3bi-opsonised yeast,
which binds and activates CD11b/CD18 [25], the b2-integrin
signalling was significantly decreased in neutrophils from CAD
patients compared to controls. This reduced response to C3bi-
opsonised yeast might also reflect the adhesive property of the b2-
integrin [26], but regardless of whether the observed down-
regulated signalling capacity was due to a dysfunctional signalling
capacity per se or resulted from decreased adhesion, the results
indicate that inside-out signalling regulating CD11b/CD18-
Figure 4. IL-8 and LTB4 induced ROS production in neutrophils from patients with stable CAD. The production of ROS in response to (A–B) IL-8
(100 ng/mL), (C–D) LTB4 (100 nM), or (E–F) PMA (50 nM), was measured in isolated neutrophils from patients (black dashed line and black dot,
respectively) and individually matched controls (grey line and grey dot, respectively). Data are expressed as counts per min (cpm) and shown as one
representative histogram plot (A,C,E) or as total ROS production peak value from 9–10 experiments per cohort (B,D,F). Mean value is indicated as
a black hyphen. Wilcoxon signed-ranks test was used to determine significance between each patient and its individually matched control
(** represents significant difference; p,0.01).
doi:10.1371/journal.pone.0001056.g004
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PLoS ONE | www.plosone.org 6 October 2007 | Issue 10 | e1056integrin avidity was down-regulated in patients with stable CAD.
In addition, the non-receptor-mediated ROS production by PMA
was significantly decreased in patients, suggesting that the optimal
capacity to generate ROS was deficient in patients. Altogether, our
data point towards a dysfunctional activation status of neutrophils
in CAD patients, involving cellular processes mediated by b2-
integrins.
In contrast to our previous data [11], the CAD patients in the
present study were without signs of systemic inflammatory activity,
as assessed by CRP and neutrophil counts. One plausible
explanation is that each patient in the present study was treated
with both low-dose aspirin and statin. Aspirin and statin are both
well known CRP-lowering agents (reviewed in: [27]). A primed
neutrophil response has also been shown to attenuate upon
therapy with these drugs. By affecting protein prenylation, statin
modulates a variety of signalling molecules; many of which are
involved in regulating adhesion (reviewed in: [28]). In high-risk
individuals, a 4-week treatment with statin was able to reduce the
synthesis of IL-8 in neutrophils and decrease the neutrophil
migration and chemotaxis [9]. Aspirin influence a number of
mechanisms and signalling pathways involved in neutrophil
activation, for instance attenuating the expression of IL-8 [29]
and the LTB4-induced migration of neutrophils [8]. Aspirin-
triggered lipoxins attenuates the expression of b2-integrins [30],
decreases the LTB4-induced adhesion-state of neutrophils by
affecting the avidity of the b2-integrin [31], and inhibits neutrophil
adhesion to activated endothelial cells [32].
To conclude, the present study does not give any support for
a role of neutrophil priming in stable CAD. The neutrophils in
patients with stable CAD were not more activated in vivo than were
cells in healthy controls, neither were the neutrophils in patients
more prone to activation ex vivo. Rather, the neutrophils in patients
displayed a decreased b2-integrin signalling and/or adhesion
capacity and a deficient intrinsic capacity to generate ROS.
Although the results indicate that the drug therapy of today is
efficient in maintaining the neutrophils in a non-adhesive manner;
an outcome that most certainly has a positive impact on the
prognosis, the clinical relevance of neutrophil dysfunction in CAD
remains to be elucidated. Is it mainly a marker of chronic
inflammatory disease or a factor with impact on the progress of
CAD?
MATERIALS AND METHODS
Subjects
Thirty patients with angiographically verified stable CAD were
recruited from the Department of Cardiology, Heart Centre,
Linko ¨ping University Hospital, Sweden. The patients had effort-
related angina in accordance with the Canadian Cardiovascular
Society functional classes I and II without any worsening of
symptoms the latest 6 months. Patients were excluded if they
were.65 years old, had severe heart failure, immunologic
disorders, neoplasm disease, evidence of acute or recent
(,2 months) infection, recent major trauma, surgery or re-
vascularization procedure, or treatment with immunosuppressive
or anti-inflammatory agents (except low-dose aspirin). Each
patient was matched, regarding age and sex, with a clinically
healthy control randomly selected from a population register
representing the hospital recruitment area. The control subjects
were anamnestically healthy and with normal routine laboratory
tests. All patients and control persons gave informed oral consent.
The appointed ethics committee at Linko ¨ping University approved
the research protocol, and the study was conducted in accordance
with the ethical guidelines of Declaration of Helsinki.
Collection of blood
For each experimental set-up, venous peripheral blood was drawn
from one patient and its matched control in the morning after
a 12 h fast, and collected in heparin-containing vacutainer tubes.
The samples were blinded during all experiments.
Flow cytometry
Immuno-labelling was performed, as previously described [31], to
investigate changes in the total expression of b2-integrin and in the
expression of b2-integrins displaying the high-affinity epitope. In
short, whole blood (50 ml/sample) was pre-heated at 37uC. In
order to study the high-affinity state of the b2-integrin, a mono-
clonal FITC-conjugated mouse anti-human CD11b antibody
recognizing the ligand binding domain (i.e., the I-domain [33];
CBRM1/5; Biosite) was used. This antibody was given 1 min
before stimulation with Interleukin-8 (IL-8; Sigma-Aldrich) or and
Leukotriene B4 (LTB4; Larodan Fine Chemicals AB). In samples
used for detecting the plasma membrane expression of CD18, the
monoclonal FITC-conjugated mouse anti-human CD18 antibody
(MHM23; DakoCytomation) was added 5 min after stimulation.
For all samples, the stimulation was stopped by incubating the
samples on ice. Contaminating erythrocytes were removed by ice-
cold cell lysis (NH4Cl 150 mM, KHCO3 10 mM, EDTA 100 mM)
for 5 min at 15uC. The cells were collected and fixed in ice-cold
0.1% paraformaldehyde (PFA). Mean fluorescence values from 10
000 cells/sample were determined by flow cytometry using
a Becton Dickinson FACSCalibur (Becton Dickinson, San Jose,
CA/USA). Cell populations were identified by plotting FSC versus
SSC excluding cell debris, followed by gating and further analysis
of the neutrophil (granulocyte) population (Fig. 5). Auto-fluores-
cence of unstained cells was routinely analyzed. Unspecific binding
was determined using a FITC-conjugated isotypic mouse anti-
human IgG1 (DakoCytomation).
Preparation of neutrophils
Neutrophils were prepared by density gradient centrifugation, as
previously described [31]. In short, freshly drawn heparinized
Figure 5. A representative gating to identify the neutrophil
population in the flow cytometry analysis. G: Granulocytes, M:
Monocytes, L: Lymphocytes, FSC: Forward scatter, SSC: Side scatter.
doi:10.1371/journal.pone.0001056.g005
Leukocytes in Coronary Disease
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TM and Polymorph-
prep
TM (Axis-Shield AS), and centrifuged in a swing-out centrifuge
(4006g, 30 min, RT). The granulocyte band was collected,
washed and resuspended in a small volume of PBS (pH 7.3;
made in-house), and concentrated by a short spin. Contaminating
erythrocytes were removed by hypotonic lysis, and the cells were
washed, resuspended in Krebs-Ringer glucose buffer (KRG;
10 mM glucose, 1 mM Ca
2+, and 1.2 mM Mg
2+; pH 7.3; made
in-house) without Ca
2+, and kept on ice.
Opsonization of yeast particles
Serum opsonized yeast particles were prepared, as previously
described [34]. In short, heat killed yeast (Saccharomyces cerevisiae)
were opsonized with 25% normal human serum (AB
2) for 30 min
at 37uC. The yeast particles were resuspended in KRG,
homogenized, and adjusted to a concentration to 5610
7/mL,
before added as stimuli at ratio 5:1 (yeast/cell).
Determination of ROS production
Chemiluminescence was used to determine the ROS production
of isolated neutrophils from 10 patients with stable CAD and 10
control subjects, respectively. The measurements were performed,
as previously described [35], using a six-channel Biolumat LB9505
(Berthold Co., Wildbad, Germany). Neutrophils (5610
6/mL) were
diluted in KRG in polypropylene tubes to a total volume of 1 mL
(after addition of the stimulus). Total ROS production was
measured using luminol (5-amino-2,3-dihydro-1,4-phthalazine-
dione; 56 mM; Sigma), and horseradish peroxidase (HRP; 4 U/
mL; Roche). For measurements of the intracellular ROS pro-
duction samples contained luminol (56 mM), superoxide dismutase
(SOD; 50 U/mL; Roche) and catalase (2000 U/mL; Roche).
Extracellular ROS production was measured using isoluminol (6-
amino-2,3-dihydro-1,4-phthalazinedione; 56 mM; Sigma) and
HRP (4 U/mL). The samples were pre-heated for 5 min before
addition of stimuli, and the temperature was kept at 37uC during
the measurements. Light emission, reflecting ROS interacting with
luminol/isoluminol was continuously monitored. The peak value
was registered for each sample, and expressed as counts per
minute (cpm). PMA (Phorbol 12-myristate 13-acetate; Sigma),
which directly activate protein kinase C, was used to examine the
maximal ROS production elicited in the cells.
Statistics
Statistics were performed using the SPSS program (version 11.5).
For all clinical and laboratory characteristics, non-parametric tests
were used since data, in general, were non-normally distributed.
These data were presented as median (inter-quartile range). The
significance of any difference between patients and controls was
tested by using Mann-Whitney U-test. Data on b2-integrin state
and ROS production were analysed by Wilcoxon signed rank test
to compare levels between a patient and its paired control. A
p,0.05 was considered significant.
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